

**SUGGESTED FORMULA****Amantadine HCl 50 mg/5 mL OralSyrup**

Version number: 1.0

Volume: 480mL

---

Amantadine Hydrochloride, USP (AM102)	4.8 g
Glycerin, Natural, USP (G1016)	30 mL
Saccharin Sodium (Dihydrate), USP (SO200)	0.24 g
Stevia Leaves Extract, Sweet, Powder (S1964)	3.6 g
*Preserved Water (parabens)	125 mL
Citric Acid, Monohydrate, USP (C1296)	0.48 g
Raspberry Flavor, Artificial, Concentrate (R1057)	15 mL
Sorbitol Solution, USP 70% (w/w) (SO220)	q.s. 480 mL

---

**\*Formulation for Preserved Water can be found at [SpectrumRx.com>Services>Formulations](https://www.spectrumrx.com/Services/Formulations)**

**SUGGESTED COMPOUNDING PROCEDURES**

1. Check calculations and weigh all ingredients.
2. Dissolve Amantadine Hydrochloride in an appropriately sized beaker in preserved water; use an amount that is approximately 20% of the specified amount. For example 20% of the specified amount of 125 mL is 25 mL.
3. In a separate beaker, dissolve Stevia in preserved water and use approximately 60% of the specified amount (i.e. 75 mL)
4. Combine steps 2 and 3 and add Citric Acid. Stir until dissolved.
5. Add Sorbitol Solution and glycerin to step 4 and use an amount of Sorbitol approximately equal to 25% of the final volume (i.e. 25% of 480 mL is 120 mL).
6. In another beaker, dissolve Saccharin Sodium in preserved water then add to step 5. Use approximately 20% of the specified amount (i.e. 25 mL).
7. Mix flavor into step 6.
8. Bring step 7 to the final volume with Sorbitol Solution, and mix well.
9. Package and label.
10. Suggested Quality Assessments—follow pharmacy SOPs:
  - a. Weight to Volume calculation
  - b. Color
  - c. Clarity
  - d. Label - auxiliary labels, storage, BUD, compounded medication

Store in air tight amber plastic containers refrigerated.

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates by the formulator using reference books, peer-reviewed literature, intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

**Beyond-Use Date is estimated to be 14 days refrigerated.**

Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate protective equipment. Use safety enclosures (hoods) when weighing and mixing.

12/17 RD